HAZARDOUS AGENT INJECTION SYSTEM
2 Assignments
0 Petitions
Accused Products
Abstract
Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
-
Citations
46 Claims
-
1-21. -21. (canceled)
-
22. A jet injector comprising:
-
a container configured to contain an amount of methotrexate; a injection outlet member configured to be associated with the container; a firing mechanism configured to expel the methotrexate from the container through the outlet member for injecting the methotrexate; an energy source associated with the firing mechanism to power the firing mechanism and jet inject the methotrexate from the injection outlet as a fluid jet; and a trigger mechanism associated with the firing mechanism to activate the firing mechanism. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
-
38. An injection system for the treatment of rheumatoid arthritis, comprising:
-
a container configured to contain an amount of methotrexate that is therapeutically effective to treat rheumatoid arthritis; and a needle-assisted jet injector comprising; a injection outlet member configured to be associated with the container, wherein the outlet member has an injection-assisting needle configured to pierce the skin of a patient; a firing mechanism configured to expel all of the methotrexate from the container through the injection-assisting needle for injecting the methotrexate into the patient subcutaneously; an energy source associated with the firing mechanism to power the firing mechanism and jet inject the methotrexate from the injection-assisting needle as a fluid jet; and a trigger mechanism associated with the firing mechanism to activate the firing mechanism; wherein the jet injector is configured to eject the methotrexate from the injection outlet member such that the pharmacokinetics of the jet injected methotrexate are bioequivalent to the pharmacokinetics of methotrexate delivered by a hand powered syringe. - View Dependent Claims (39, 40, 41)
-
- 42. A method of treating rheumatoid arthritis, comprising delivering a therapeutically effective amount of methotrexate by needle-assisted jet injection to a patient such that the pharmacokinetics of the jet injected methotrexate are bioequivalent to the pharmacokinetics of methotrexate delivered by a hand powered syringe.
Specification